Literature DB >> 12065468

DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge.

Charlene J Repique1, Amy Li, Frank M Collins, Sheldon L Morris.   

Abstract

Individuals who are latently infected with Mycobacterium tuberculosis can develop active disease via either endogenous reactivation of the latent bacilli or exogenous reinfection with a second mycobacterial strain. In this study, we investigated whether immunization with a tuberculosis DNA vaccine cocktail that induces significant protective responses in mice could prevent reactivation of disease in a murine latent-tuberculosis model. In addition, we assessed whether DNA vaccination could retard the growth of a secondary aerogenic infection with M. tuberculosis (exogenous reinfection) in latently infected mice. In the reactivation studies, administration of the DNA vaccine combination did not prevent recrudescence of the latent infection after injection of dexamethasone. Moreover, for the reinfection experiments, only a modest decrease in the growth of a secondary M. tuberculosis challenge in DNA-vaccinated animals, compared to controls, was observed 14 and 28 days after the reinfection of previously exposed mice. Interestingly, although proliferation of the secondary challenge was reduced significantly in a nonvaccinated chronic-infection group relative to the naïve controls, the number of bacilli still increased by 500-fold 1 month after the secondary challenge in mice with active tuberculosis. These results indicate that novel immunotherapeutic approaches will be required to prevent reactivation of infection or reinfection of individuals with latent tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065468      PMCID: PMC128037          DOI: 10.1128/IAI.70.7.3318-3323.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Exogenous reinfection with tuberculosis on a European island with a moderate incidence of disease.

Authors:  J A Caminero; M J Pena; M I Campos-Herrero; J C Rodríguez; O Afonso; C Martin; J M Pavón; M J Torres; M Burgos; P Cabrera; P M Small; D A Enarson
Journal:  Am J Respir Crit Care Med       Date:  2001-03       Impact factor: 21.405

Review 2.  Heat shock proteins: the 'Swiss Army Knife' vaccines against cancers and infectious agents.

Authors:  P K Srivastava; R J Amato
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

3.  Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode.

Authors:  J Turner; E R Rhoades; M Keen; J T Belisle; A A Frank; I M Orme
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

Review 4.  Tuberculosis vaccine development: recent progress.

Authors:  I M Orme; D N McMurray; J T Belisle
Journal:  Trends Microbiol       Date:  2001-03       Impact factor: 17.079

5.  The immunogenicity of single and combination DNA vaccines against tuberculosis.

Authors:  S Morris; C Kelley; A Howard; Z Li; F Collins
Journal:  Vaccine       Date:  2000-04-14       Impact factor: 3.641

6.  DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity.

Authors:  G Delogu; A Howard; F M Collins; S L Morris
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

7.  Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology.

Authors:  V P Mohan; C A Scanga; K Yu; H M Scott; K E Tanaka; E Tsang; M M Tsai; J L Flynn; J Chan
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

8.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project.

Authors:  C Dye; S Scheele; P Dolin; V Pathania; M C Raviglione
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

9.  Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells.

Authors:  L A van Pinxteren; J P Cassidy; B H Smedegaard; E M Agger; P Andersen
Journal:  Eur J Immunol       Date:  2000-12       Impact factor: 5.532

10.  Depletion of CD4(+) T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon gamma and nitric oxide synthase 2.

Authors:  C A Scanga; V P Mohan; K Yu; H Joseph; K Tanaka; J Chan; J L Flynn
Journal:  J Exp Med       Date:  2000-08-07       Impact factor: 14.307

View more
  12 in total

Review 1.  On the use of DNA vaccines for the prophylaxis of mycobacterial diseases.

Authors:  Kris Huygen
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

Review 2.  Latent tuberculosis infection: myths, models, and molecular mechanisms.

Authors:  Noton K Dutta; Petros C Karakousis
Journal:  Microbiol Mol Biol Rev       Date:  2014-09       Impact factor: 11.056

Review 3.  Mixed-strain mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control.

Authors:  Ted Cohen; Paul D van Helden; Douglas Wilson; Caroline Colijn; Megan M McLaughlin; Ibrahim Abubakar; Robin M Warren
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

4.  Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in mice.

Authors:  Bo Young Jeon; Steven C Derrick; Jaehyun Lim; Kristopher Kolibab; Veerabadran Dheenadhayalan; Amy Li Yang; Barry Kreiswirth; Sheldon L Morris
Journal:  Infect Immun       Date:  2008-08-18       Impact factor: 3.441

5.  Pulmonary necrosis resulting from DNA vaccination against tuberculosis.

Authors:  Jennifer L Taylor; Oliver C Turner; Randall J Basaraba; John T Belisle; Kris Huygen; Ian M Orme
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

6.  Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB.

Authors:  Dmitry A Butov; Yuri N Pashkov; Anna L Stepanenko; Aleksandra I Choporova; Tanya S Butova; Dendev Batdelger; Vichai Jirathitikal; Aldar S Bourinbaiar; Svetlana I Zaitzeva
Journal:  J Immune Based Ther Vaccines       Date:  2011-01-18

7.  The use of anti-tuberculosis therapy for latent TB infection.

Authors:  Justin T Denholm; Emma S McBryde
Journal:  Infect Drug Resist       Date:  2010-07-21       Impact factor: 4.003

8.  Immunotherapeutic role of Ag85B as an adjunct to antituberculous chemotherapy.

Authors:  Javaid A Sheikh; Gopal K Khuller; Indu Verma
Journal:  J Immune Based Ther Vaccines       Date:  2011-06-26

9.  Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection.

Authors:  Teresa G Martins; José B Gama; Alexandra G Fraga; Margarida Saraiva; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

10.  Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi.

Authors:  Amelia C Crampin; J Nimrod Mwaungulu; Frank D Mwaungulu; D Totah Mwafulirwa; Kondwani Munthali; Sian Floyd; Paul Em Fine; Judith R Glynn
Journal:  AIDS       Date:  2010-01-28       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.